Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NICOLAS trial: what clinicians have said so far
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
- NCT02434081 ↗
- Completed
- ETOP IBCSG Partners Foundation
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NICOLAS yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NICOLAS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer Stage III
- Interventions
- Nivolumab
- Arms
- Chemo-radiotherapy with concurrent nivolumab · Experimental
- Enrollment
- 94
- Primary outcomes
- Grade ≥3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy
- Sponsor
- ETOP IBCSG Partners Foundation with Bristol-Myers Squibb, Frontier Science Foundation, Hellas
- Start
- Nov 25, 2015
- Primary completion
- Feb 29, 2020
- Results posted
- Yes
- Registry record
- NCT02434081 · updated Aug 24, 2026
Publications
linked from the registry- Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10;31(8):1029-38. doi: 10.1200/JCO.2012.44.5064. Epub 2013 Feb 11. PubMed 23401449
- Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. PubMed 28551359